Press Releases

February 11, 2021

Bolden Therapeutics Receives Biogen-LabCentral ‘Golden Ticket’ Award

PROVIDENCE, RI. Bolden Therapeutics, Inc., a biotechnology company developing first-in-class therapeutics to promote neurogenesis for potential treatment of CNS diseases such as Alzheimer’s and ischemic stroke, today announced being awarded the Biogen-LabCentral Golden Ticket.